The Relative Benefits and Risks of Kratom Derived Products

his free, 1-hour CME course will provide an overview of natural leaf kratom, mitragynine extracts, and isolated synthetic compounds (7-OH, mitragynine pseudoindoxyl, MGM-15/16), compare their pharmacologic profiles with traditional opioids, review available clinical and anecdotal data on potential risks and benefits, and discuss regulatory strategies aimed at reducing public health harms while preserving access to natural leaf kratom.

 

 

 

 

 

 

 

Enroll in this Course!

The Relative Benefits and Risks of Kratom Derived Products

Meets DEA training requirements 

1.0 AMA PRA Category 1 Credit(s)™

Learning objectives: 

• Describe the three different types of kratom derived products (natural leaf, mitragynine extracts, and isolated synthetics (7-OH, mitragynine pseudoindoxyl, MGM-15/16)
• Compare and contrast the pharmacologic similarities and differences between kratom derived products and with traditional opioids
• Describe the clinical trial and descriptive (anecdotal) data on kratom derived products to determine the potential risks and benefits
• Describe a regulatory approach to reduce public health risk but maintain access to natural leaf kratom

Accreditation and Credit Designation

Accreditation Council for Continuing Medical Education

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of MyMichigan Health and Michigan OPEN. MyMichigan Health is accredited by the Michigan State Medical Society (MSMS) to provide continuing medical education for physicians. MyMichigan Health designates this live activity for a maximum of 1 AMA PRA Category Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.